MX2018012856A - Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. - Google Patents

Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.

Info

Publication number
MX2018012856A
MX2018012856A MX2018012856A MX2018012856A MX2018012856A MX 2018012856 A MX2018012856 A MX 2018012856A MX 2018012856 A MX2018012856 A MX 2018012856A MX 2018012856 A MX2018012856 A MX 2018012856A MX 2018012856 A MX2018012856 A MX 2018012856A
Authority
MX
Mexico
Prior art keywords
methods
therapeutic
dipeptidil
peptidase
disease
Prior art date
Application number
MX2018012856A
Other languages
English (en)
Spanish (es)
Inventor
Bergmann Andreas
Original Assignee
Sphingotec Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Therapeutics Gmbh filed Critical Sphingotec Therapeutics Gmbh
Publication of MX2018012856A publication Critical patent/MX2018012856A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
MX2018012856A 2016-04-21 2017-04-20 Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. MX2018012856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16166476 2016-04-21
PCT/EP2017/059377 WO2017182561A1 (en) 2016-04-21 2017-04-20 Methods for determining dpp3 and therapeutic methods

Publications (1)

Publication Number Publication Date
MX2018012856A true MX2018012856A (es) 2019-07-10

Family

ID=56014788

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018012856A MX2018012856A (es) 2016-04-21 2017-04-20 Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
MX2025006655A MX2025006655A (es) 2016-04-21 2018-10-19 Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos
MX2020001193A MX2020001193A (es) 2016-04-21 2018-10-19 Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2025006655A MX2025006655A (es) 2016-04-21 2018-10-19 Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos
MX2020001193A MX2020001193A (es) 2016-04-21 2018-10-19 Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.

Country Status (15)

Country Link
US (3) US20190145981A1 (cg-RX-API-DMAC7.html)
EP (5) EP3854817A1 (cg-RX-API-DMAC7.html)
JP (4) JP2019520550A (cg-RX-API-DMAC7.html)
KR (3) KR102886883B1 (cg-RX-API-DMAC7.html)
CN (3) CN110168372A (cg-RX-API-DMAC7.html)
AU (2) AU2017252212B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018071583A2 (cg-RX-API-DMAC7.html)
CA (1) CA3021252A1 (cg-RX-API-DMAC7.html)
CH (1) CH713803B1 (cg-RX-API-DMAC7.html)
DE (1) DE112017002105T5 (cg-RX-API-DMAC7.html)
IL (1) IL262472B2 (cg-RX-API-DMAC7.html)
MX (3) MX2018012856A (cg-RX-API-DMAC7.html)
MY (1) MY200300A (cg-RX-API-DMAC7.html)
SG (1) SG11201809252YA (cg-RX-API-DMAC7.html)
WO (1) WO2017182561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190145981A1 (en) * 2016-04-21 2019-05-16 Sphingotec Therapeutics Gmbh Methods for determining dpp3 and therapeutic methods
US11530276B2 (en) * 2017-10-25 2022-12-20 4TEEN4 Pharmaceuticals GmbH DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
CN113557031A (zh) * 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
EP4552649A3 (en) * 2019-08-30 2025-06-25 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
IL295728A (en) 2020-02-27 2022-10-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
AU2021228207A1 (en) * 2020-02-27 2022-10-20 4TEEN4 Pharmaceuticals GmbH DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
IL295951A (en) 2020-02-27 2022-10-01 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
EP4121763A1 (en) * 2020-03-16 2023-01-25 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP3922993A1 (en) * 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2023175035A1 (en) 2022-03-15 2023-09-21 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
CN117186177B (zh) * 2022-05-31 2024-08-23 中国农业大学 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法
CN119630969A (zh) 2022-07-29 2025-03-14 4Teen4制药有限公司 预测患有败血症性休克的患者中的dpp3增加
KR20250042158A (ko) 2022-07-29 2025-03-26 아드레노메드 아게 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
CN120359042A (zh) 2022-12-15 2025-07-22 4Teen4制药有限公司 改善危重病患者肺功能的dpp3抑制剂
CN115804836A (zh) * 2022-12-27 2023-03-17 中国人民解放军海军特色医学中心 一种中枢小分子蛋白dpp3在制备降压药物中的应用
CN120857945A (zh) 2023-03-29 2025-10-28 4Teen4制药有限公司 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JPH06219989A (ja) * 1993-01-27 1994-08-09 Microbial Chem Res Found 新規生理活性物質フルオスタチンａおよびｂ、その製造法およびその用途
GB9312324D0 (en) * 1993-06-15 1993-07-28 Pitman Moore Inc Vaccine
US5612186A (en) 1994-06-22 1997-03-18 Food Industry Research And Development Institute Enzyme-capture assay (ECA) for the identification of Escherichia coli in clinical samples
US5601986A (en) 1994-07-14 1997-02-11 Amgen Inc. Assays and devices for the detection of extrahepatic biliary atresia
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001016334A2 (en) 1999-09-01 2001-03-08 Incyte Genomics, Inc. Human hydrolytic enzymes
US6864363B2 (en) * 2000-11-08 2005-03-08 University Of Georgia Research Foundation, Inc. Dipeptidylpeptidases and methods of use
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2005106486A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005118842A1 (ja) * 2004-06-01 2005-12-15 Sysmex Corporation 酵素活性測定方法および酵素活性測定用カラム
EP1793847A2 (en) 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
JP2006230318A (ja) 2005-02-25 2006-09-07 Maruishi Pharmaceutical Co Ltd 関節リウマチの診断方法
CN100420947C (zh) * 2005-05-30 2008-09-24 孙东旭 用单一捕获剂定量检测特异性分析物的方法及其试剂盒
WO2007055979A2 (en) * 2005-11-02 2007-05-18 Meyer Pharmaceuticals Llc Native trre: protein implicated in tnf receptor shedding for treating arthritis and inflammation
JP5410955B2 (ja) 2006-03-13 2014-02-05 ベクトン・ディキンソン・アンド・カンパニー ジペプチジルペプチダーゼ関連の疾患状態の診断および予後
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
US8715928B2 (en) * 2009-02-13 2014-05-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
KR101234352B1 (ko) * 2010-03-18 2013-02-15 권동락 선택적 면역 세포 분리 반출장치
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
US20190145981A1 (en) * 2016-04-21 2019-05-16 Sphingotec Therapeutics Gmbh Methods for determining dpp3 and therapeutic methods

Also Published As

Publication number Publication date
MX2025006655A (es) 2025-07-01
JP2020127409A (ja) 2020-08-27
EP4417217A3 (en) 2024-11-13
JP2022163014A (ja) 2022-10-25
AU2017252212B2 (en) 2023-09-07
EP3854817A1 (en) 2021-07-28
RU2018140832A (ru) 2020-05-21
EP3446125A1 (en) 2019-02-27
CH713803B1 (de) 2023-08-15
EP3446125C0 (en) 2024-08-28
CA3021252A1 (en) 2017-10-26
US20200378977A1 (en) 2020-12-03
IL262472A (en) 2018-12-31
WO2017182561A1 (en) 2017-10-26
US11726094B2 (en) 2023-08-15
CN120992960A (zh) 2025-11-21
JP2019520550A (ja) 2019-07-18
EP4417218A2 (en) 2024-08-21
AU2017252212A1 (en) 2018-11-08
KR20190003959A (ko) 2019-01-10
IL262472B2 (en) 2024-12-01
US20240385197A1 (en) 2024-11-21
EP4417217A2 (en) 2024-08-21
KR102565453B1 (ko) 2023-08-11
AU2023258417A1 (en) 2023-11-23
MY200300A (en) 2023-12-19
EP3896450A1 (en) 2021-10-20
KR102886883B1 (ko) 2025-11-19
EP4417218A3 (en) 2024-11-13
SG11201809252YA (en) 2018-11-29
JP7219737B2 (ja) 2023-02-08
BR112018071583A2 (pt) 2019-02-12
EP3446125B1 (en) 2024-08-28
KR102886863B1 (ko) 2025-11-18
RU2018140832A3 (cg-RX-API-DMAC7.html) 2020-08-14
US20190145981A1 (en) 2019-05-16
KR20230123520A (ko) 2023-08-23
CN120093910A (zh) 2025-06-06
MX2020001193A (es) 2020-03-20
JP2025011237A (ja) 2025-01-23
DE112017002105T5 (de) 2019-04-25
CN110168372A (zh) 2019-08-23
KR20240122910A (ko) 2024-08-13
NZ747387A (en) 2024-10-25
IL262472B1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
CL2018002359A1 (es) Métodos para usar agonistas de fxr
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
EA201992546A1 (ru) Средства на основе антител к cd33
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
EP3490677A4 (en) LIPID, PROTEIN AND METABOLITE MARKER FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
MX2017009038A (es) Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
AR110378A1 (es) Métodos para determinar el estado del cáncer colorrectal en una persona
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
MX380889B (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson.
BR112019005172A2 (pt) método e kit para analisar uma amostra
MX2022001087A (es) Ergotioneina, s-metil-ergotioneina, y usos de las mismas.
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
EA201990720A1 (ru) Способы детекции нейтрализующих антител к лептину
CL2020003168A1 (es) Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis
DK3161165T3 (da) Fremgangsmåde til diagnosticering af subklinisk og klinisk akut afstødning ved analyse af prædiktive gensæt, terapeutisk middel til anvendelse ved behandlingen og kits til at bestemme ekspressionen
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
MX2024009782A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?